---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124543"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:33:21.802863+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agenus Q3 2024 net loss $67.2M, cash $44.8M; BOT/BAL shows MSS CRC promise

## Summary
- Cash $44.8M at Sept 30, 2024 (vs $76.1M Dec 2023); raised $7.1M via ATM post-quarter.
- Q3 2024 revenue $25.1M (non-cash); net loss $67.2M; cash used in ops 9M 2024 $129.7M (down from $183.8M YoY).
- BOT/BAL combination shows unprecedented outcomes in neoadjuvant MSS CRC (ESMO GI 2024) and advanced sarcomas (ESMO 2024).
- Strategic initiatives: real estate monetization discussions advancing; near-term transaction expected to deliver substantial resources.
- EMA agreement on dose selection and trial design for Phase 3 study in MSS CRC.

## SEC filing metadata
- accession: 0000950170-24-124543
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000095017024124543/0000950170-24-124543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000095017024124543/agen-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124543
- JSON: https://secwatch.observer/filing/0000950170-24-124543.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.